Clinical Trials
76 trialsRAINFOL-01
Genmab
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Regeneron Pharmaceuticals
CERTIS1
AstraZeneca
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
National Cancer Institute (NCI)
OVATION 2
Imunon
MRD
Imunon
Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
ELUCIDATE
Exscientia AI Limited
FRAPPE
Mayo Clinic
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Artios Pharma Ltd
A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
DUAL-OV-CAR-NK
Beijing Biotech
PROOV
The Netherlands Cancer Institute
A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum Resistance Ovarian Cancer
Bio-Thera Solutions
CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer
TORL Biotherapeutics, LLC
Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)
M.D. Anderson Cancer Center
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
Regeneron Pharmaceuticals
Study of AVZO-021 in Patients With Advanced Solid Tumors
Avenzo Therapeutics, Inc.
MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Mayo Clinic
A Study of PF-06873600 in People With Cancer
Pfizer
T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer
Herlev Hospital
A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors
Incyte Corporation
ABILITY-1
Medicenna Therapeutics, Inc.
Surgery for Relapsed Ovarian Cancer in Precision
Shanghai Gynecologic Oncology Group
Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1
Roswell Park Cancer Institute
AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
M.D. Anderson Cancer Center
KANDOVA
Novakand Pharma AB
Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NRG Oncology
PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer
New Mexico Cancer Research Alliance
A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors
Numab Therapeutics AG
Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer
City of Hope Medical Center
Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC)
Jonsson Comprehensive Cancer Center
Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer
Pfizer
A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
23andMe, Inc.
EDO-S101
Mundipharma Research Limited
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)
Elucida Oncology
Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer
ImmunoGen, Inc.
Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer
The Netherlands Cancer Institute
A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary
Avenge Bio, Inc
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
Sumitomo Pharma America, Inc.
Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Fox Chase Cancer Center
A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy
THERAPIM PTY LTD
Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer
Syndax Pharmaceuticals
Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Roswell Park Cancer Institute
A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)
pharmaand GmbH
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
Roswell Park Cancer Institute
GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer
Genelux Corporation
A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor
Clovis Oncology, Inc.